Drug intelligence / Profile preview

Renaparin

Development stage: Phase 1
Lead developer: Corline Biomedical
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Organ Perfusion

Overview

Renaparin is a heparin-conjugate macromolecular drug developed by Corline Biomedical for the prevention of delayed graft function and ischemia-reperfusion injury in solid organ transplantation, primarily kidney transplantation. It is administered by flushing the vessel system of the kidney ex vivo prior to transplantation to repair damaged blood vessels and protect against innate immune response-mediated injury. The drug acts as an endothelial cell modulator and has shown efficacy in reducing reperfusion injury in preclinical models. Renaparin has received orphan drug designation in the EU for transplant rejection and is currently in Phase I clinical trials for renal transplant rejection[1][2][4].

Brand names: Renaparin
Other names: Corline Heparin ConjugateCHC

Beyond the preview

Go deeper on Renaparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renaparin.

Explore the full profile